

AmeriHealth Caritas Louisiana

National Imaging Associates, Inc.*	
Clinical guidelines ABDOMEN MRA (Angiography)	Original Date: September 1997
CPT Codes: 74185	Last Revised Date: May 2020
Guideline Number: NIA_CG_034-2	Implementation Date: January 2021 TBD

GENERAL INFORMATION:

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. All prior relevant imaging results, and the reason that alternative imaging (gold standard, protocol, contrast, etc.) cannot be performed must be included in the documentation submitted.

INDICATIONS FOR ABDOMEN MR Angiography/MR Venography:

For evaluation of known or suspected abdominal vascular disease:

Arterial Disease:

- Evaluation of known or suspected aortic aneurysm (also approve MRA pelvis) (Chaikof, 2018; Khosa, 2013; Khumar, 2017; ~~Khosa, 2013~~):
 - For screening, US is initial study
 - Known or suspected aneurysm > 2.5 cm AND equivocal or indeterminate ultrasound results;
 - Prior imaging (e.g. ultrasound) demonstrating aneurysm >2.5 cm in diameter;
 - Suspected complications of known aneurysm as evidenced by signs/symptoms such as new onset of abdominal or pelvic pain.
 - Surveillance imaging every three years for diameter 2.0-2.9 cm and annually for 3.0-3.4 cm if doppler ultrasound is inconclusive. If > 3.5 cm, < 6 month follow up (and consider intervention) (Wainhainen, 2019)
- For known large vessel diseases (abdominal aorta, inferior vena cava, superior/inferior mesenteric, celiac, splenic, renal or iliac arteries/veins), e.g., aneurysm, dissection, **compression syndromes**, arteriovenous malformations (AVMs), and fistulas, intramural hematoma, and vasculitis **limited to the abdomen**.
- For suspected aortic dissection (approve CTA/MRA ~~a~~-abdomen and pelvis)

* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

- For diagnosis or follow up of visceral artery aneurysm (Ibrahim, 2018; Junternamms, 2018)
- To determine the vascular source of retroperitoneal hematoma or hemorrhage (to determine a vascular source of hemorrhage in the setting of trauma, tumor invasion, fistula or vasculitis when CTA is contraindicated)
- For evaluation of suspected acute mesenteric ischemia/ischemic colitis when CTA is contraindicated (ACR, 2018).
- For suspected chronic mesenteric ischemia
For May Thurner syndrome (include pelvic MRV) (Ibrahim 2012; Wan-Ling, 2012)
- Evidence of vascular abnormality seen on prior imaging studies and limited to the abdomen.
- For evaluation of known or suspected renal artery stenosis or resistant hypertension in the setting of normal renal function or impaired renal function unrelated to recent medication (ACR, 2017) demonstrated by any of the following (Hartman, 2009; Tullus, 2010):
 - Unsuccessful control after treatment with 3 or more (>2) anti-hypertensive medication at optimal dosing.
 - Acute elevation of creatinine after initiation of an angiotension converting enzyme inhibitor (ACE inhibitor) or angiotension receptor blocker (ARB).
 - Asymmetric kidney size noted on ultrasound.
 - Onset of hypertension in a person younger than age 30 without any other risk factors or family history of hypertension.
 - Significant hypertension (diastolic blood pressure > 110 mm Hg) in a young adult (i.e., younger than 35 years) suggestive of fibromuscular dysplasia
 - Diagnosis of a syndrome with a higher risk of vascular disease, such as neurofibromatosis, tuberous sclerosis and Williams' syndrome
 - New onset of hypertension after age 50.
 - Acute rise in blood pressure in a person with previously stable blood pressures.
 - Flash pulmonary edema without identifiable causes.
 - Malignant hypertension.
 - Bruit heard over renal artery and hypertension.

Venous Disease

- Suspected renal vein thrombosis in patient with known renal mass or from other causes (Mazhar, 2018).
- Venous thrombosis if previous studies have not resulted in a clear diagnosis (add pelvis MRA/MRV when appropriate).
- For diffuse unexplained lower extremity edema with negative or inconclusive ultrasound (Hoshino, 2016)
- For May-Thurner syndrome (include pelvic MRV) (Ibrahim 2012; Wan-Ling, 2012)
- In pregnant women with suspected deep venous thrombosis (DVT) (vs serial compression ultrasound) (include pelvis MRV for iliac veins) (Bates, 2018)

Pre-operative evaluation:

- Evaluation prior to interventional vascular procedures for luminal patency versus restenosis due to conditions such as atherosclerosis, thromboembolism, and intimal hyperplasia.
- For pre transplant evaluation of either liver or kidney.
- Imaging of the deep inferior epigastric arteries for surgical planning (breast reconstruction surgery), include pelvic MRA (ACR, 2017)

Post-operative or post-procedural evaluation:

- Evaluation of endovascular/interventional abdominal vascular procedures for luminal patency versus restenosis due to conditions such as atherosclerosis, thromboembolism, and intimal hyperplasia.
- Evaluation of post-operative complications, e.g. pseudoaneurysms, related to surgical bypass grafts, vascular stents, and stent-grafts in the peritoneal cavity.
- Follow-up for post-endovascular repair (EVAR) or open repair of abdominal aortic aneurysm (AAA) or abdominal extent of iliac artery aneurysms.
 - Routine, baseline study (post-op/intervention) is warranted within 1-3 months (abdomen and pelvis MRA when CTA is inconclusive) (Chaikof, 2018; Uberoi, 2011).
 - Asymptomatic at six (6) month intervals for one (1) year, then annually.
 - Symptomatic/complications related to stent graft – more frequent imaging may be needed
- Follow-up study may be needed to help evaluate a patient’s progress after treatment, procedure, intervention, or surgery. Documentation requires a medical reason that clearly indicates why additional imaging is needed for the type and area(s) requested.

Other Vascular indications:

- For patients with fibromuscular dysplasia (FMD), a one-time vascular study of the abdomen and pelvis (CTA or MRA) (Kadian-Dodov, 2016)
- For patients with Vascular Ehlers-Danlos syndrome or Marfan syndrome recommend a one-time study of the abdomen and pelvis (CTA/MRA)
- For Loetz-Dietz imaging at least every two years (Chu, 2014)
- Evaluation of known or suspected aortic aneurysm (also approve MRA pelvis)(Chaikof, 2018; Khumar, 2017; Khosa, 2013)*:
 - For screening, US is initial study
 - Known or suspected aneurysm > 2.5 cm AND equivocal or indeterminate ultrasound results; **OR**
 - Prior imaging (e.g. ultrasound) demonstrating aneurysm >2.5 cm in diameter; **OR**
 - Suspected complications of known aneurysm as evidenced by signs/symptoms such as new onset of abdominal or pelvic pain.
 - Surveillance imaging every three years for diameter 2.0-2.9 cm and annually for 3.0-3.4 cm if doppler ultrasound is inconclusive. If > 3.5 cm, < 6 month follow up (and consider intervention) (Wainhainen, 2019)
- To determine the vascular source of retroperitoneal hematoma or hemorrhage (to determine a vascular source of hemorrhage in the setting of trauma, tumor invasion, fistula or vasculitis when CTA is contraindicated)**

• Suspected renal vein thrombosis in patient with known renal mass or from other causes (Mazhar, 2018).

• For evaluation of suspected acute mesenteric ischemia/ischemic colitis when CTA is contraindicated (ACR, 2018).

• For suspected chronic mesenteric ischemia***

Venous thrombosis if previous studies have not resulted in a clear diagnosis (add pelvis MRA/MRV when appropriate).

For diffuse unexplained lower extremity edema with negative or inconclusive ultrasound (Hoshino, 2016)

• In pregnant women with suspected deep venous thrombosis (DVT) (vs serial compression ultrasound) (include pelvis MRV for iliac veins) (Bates, 2018)

• Vascular invasion or displacement by tumor.

• For evaluation of hepatic blood vessel abnormalities (aneurysm, hepatic vein thrombosis, stenosis post-transplant) after doppler ultrasound has been performed; to clarify or further evaluate ultrasound findings.

• For evaluation of transjugular intrahepatic portosystemic shunt (TIPS) when Doppler ultrasound indicates suspected complications

• Kidney failure or renal insufficiency if initial evaluation performed with Ultrasound is inconclusive.

• For evaluation of known or suspected renal artery stenosis or resistant hypertension in the setting of normal renal function or impaired renal function unrelated to recent medication (ACR, 2017) demonstrated by any of the following (Hartman, 2009; Tullus, 2010):

• Unsuccessful control after treatment with 3 or more (>2) anti hypertensive medication at optimal dosing.

• Acute elevation of creatinine after initiation of an angiotension converting enzyme inhibitor (ACE inhibitor) or angiotension receptor blocker (ARB).

• Asymmetric kidney size noted on ultrasound.

• Onset of hypertension in a person younger than age 30 without any other risk factors or family history of hypertension.

• Significant hypertension (diastolic blood pressure > 110 mm Hg) in a young adult (i.e., younger than 35 years) suggestive of fibromuscular dysplasia

• Diagnosis of a syndrome with a higher risk of vascular disease, such as neurofibromatosis, tuberous sclerosis and Williams' syndrome

• New onset of hypertension after age 50.

• Acute rise in blood pressure in a person with previously stable blood pressures.

• Flash pulmonary edema without identifiable causes.

• Malignant hypertension.

• Bruit heard over renal artery and hypertension.

•

Pre-operative evaluation:

• Evaluation prior to interventional vascular procedures for luminal patency versus restenosis due to conditions such as atherosclerosis, thromboembolism, and intimal hyperplasia.

- For pre transplant evaluation of either liver or kidney.
- Imaging of the deep inferior epigastric arteries for surgical planning (breast reconstruction surgery), include pelvic MRA (ACR, 2017)

Post-operative or post-procedural evaluation:

- Evaluation of endovascular/interventional abdominal vascular procedures for luminal patency versus restenosis due to conditions such as atherosclerosis, thromboembolism, and intimal hyperplasia.
- Evaluation of post-operative complications, e.g. pseudoaneurysms, related to surgical bypass grafts, vascular stents, and stent grafts in the peritoneal cavity.
- Follow up for post endovascular repair (EVAR) or open repair of abdominal aortic aneurysm (AAA) or abdominal extent of iliac artery aneurysms.
 - Routine, baseline study (post-op/intervention) is warranted within 1–3 months (abdomen and pelvis MRA when CTA is inconclusive) (Chaikof, 2018; Uberoi, 2011).
 -
 - Asymptomatic at six (6) month intervals for one (1) year, then annually.
 - Symptomatic/complications related to stent graft — more frequent imaging may be needed
 -
 - Symptomatic/complications related to stent graft — more frequent imaging may be needed
- Follow-up study may be needed to help evaluate a patient's progress after treatment, procedure, intervention, or surgery. Documentation requires a medical reason that clearly indicates why additional imaging is needed for the type and area(s) requested.

Chest MRA/Abdomen/Pelvic MRA combo:

- Acute aortic dissection -(CTA or CT preferred)(preferred) (Barman, 2014)
- Takayasi's arteritits (Kaser, 2014)
- Marfan's syndrome
- Vascular Ehlers-Danlos syndrome
- Post-operative complications

BACKGROUND:

Magnetic resonance angiography (MRA) generates images of the arteries that can be evaluated for evidence of stenosis, occlusion or aneurysms. It is used to evaluate the arteries of the abdominal aorta and the renal arteries. Contrast enhanced MRA requires the injection of a contrast agent which results in very high quality images. MRA does not use ionizing radiation, allowing MRA to be used for follow-up evaluations. Abdominal MRA is not used as a screening tool, e.g. evaluation of asymptomatic patients without a previous diagnosis.

OVERVIEW:

MRI Follow-up for post-endovascular repair (EVAR) – Although- studies have shown that MRA is as sensitive as CT in detecting endoleaks, CTA is generally the study of choice in this evaluation due to convenience, improved spatial resolution, and less artifact from components of the stent graft. MRA is most helpful in the postoperative evaluation of patients with impaired renal function, but not severe enough to have contraindication to gadolinium administration **or when CTA is inconclusive**.

Abd/Pelvis MRA & Lower Extremity MRA Runoff Requests: Two (2) authorization requests are required, one Abd MRA, CPT code 74185 and one for Lower Extremity MRA, CPT code 73725. This will provide imaging of the abdomen, pelvis, and both legs.

MRA and Abdominal Aortic Aneurysm – Endovascular repair is an alternative to open surgical repair of an abdominal aortic aneurysm. It has lower morbidity and mortality rates and is minimally invasive. In order to be successful, it depends on precise measurement of the aneurysm and involved vessels. MRA with gadolinium allows visualization of the aorta and major branches and is effective and reliable for use in planning the placement of the endovascular aortic stent graft. MRA is also used for the detection of postoperative complications of endovascular repair.

***Abdominal Aneurysms and general guidelines for follow-up:**

The normal diameter of the suprarenal abdominal aorta is 3.0 cm and that of the infrarenal is 2.0 cm. Aneurysmal dilatation of the infrarenal aorta is defined as diameter ≥ 3.0 cm or dilatation of the aorta $\geq 1.5x$ the normal diameter (Khosa, 2013). Initial evaluation of AAA is accurately made by ultrasound. Ultrasound can detect and size AAA, with the advantage of being relatively inexpensive, noninvasive and not require iodinate contrast. The limitations are that overlying bowel gas can obscure findings and the technique is operator dependent.

Asymptomatic Aneurysms require treatment when:

- The diameter is greater than 2 cm
- Identified during pregnancy
- Multiple aneurysms are present
- Hepatic transplant

Recommended intervals for initial follow-up imaging of ectatic aortas and abdominal aortas (follow up intervals may vary depending on comorbidities and the growth rate of the aneurysm) from the white paper of the ACR Incidental Findings Committee II on vascular findings (Khosa, 2013):

2.5-2.9 cm:.....5yr
3.0-3.4 cm:.....3yr
3.5-3.9 cm:.....2yr
4.0-4.4 cm:.....1yr
4.5-4.9 cm:.....6 mo
5.0-5.5 cm:.....3-6 mo

The Society of Vascular Surgery has different follow up intervals for AAA (SVS, 2018):

>2.5 cm - <3 cm.....10 yr

3.0 - 3.9 cm.....3 yr
4.0 - 4.9 cm.....12 mo
5.0 - 5.4 cm.....6 mo.

The Society of Vascular Surgery recommends elective repair of AAA \geq 5.5 cm in patients at low or acceptable surgical risk (Chaikof, 2018).

*****MRA and Chronic Mesenteric Ischemia** -“MRA has become increasingly accurate in depicting and grading stenosis of the mesenteric vessels, particularly for the celiac artery and SMA, with reported sensitivity and specificity in suspected chronic mesenteric ischemia up to 95% to 100%” and may be used for measuring flow in the SMA and superior mesenteric veins (ACR, 2018).

MRA and Renal Artery Stenosis – Renal artery stenosis is the major cause of secondary hypertension. It may also cause renal insufficiency and end-stage renal disease. Atherosclerosis is one of the common causes of this condition, especially in older patients with multiple cardiovascular risk factors and worsening hypertension or deterioration of renal function. Navigator-gated MR angiography is used to evaluate the renal arteries and detect renal artery stenosis.

MRA and Renal Vein Thrombosis – Renal vein thrombosis is a common complication of nephrotic syndrome and often occurs with membranous glomerulonephritis. Gadolinium-enhanced MRA can demonstrate both the venous anatomy and the arterial anatomy and find filling defects within renal veins. The test can be used for follow-up purposes as it does not use ionizing radiation

****MRI/CT and acute hemorrhage:** MRI is not indicated and MRA/MRV (MR Angiography/Venography) is rarely indicated for evaluation of intraperitoneal or retroperitoneal hemorrhage, particularly in the acute setting. CT is the study of choice due to its availability, speed of the study, and less susceptibility to artifact from patient motion. Advances in technology have allowed conventional CT to not just detect hematomas but also the source of acute vascular extravasation. In special cases finer vascular detail to assess the specific source vessel responsible for hemorrhage may require the use of CTA. CTA in diagnosis of lower gastrointestinal bleeding is such an example (Clerc, 2017).

MRA/MRV is often utilized in non-acute situations to assess vascular structure involved in atherosclerotic disease and its complications, vasculitis, venous thrombosis, vascular congestion or tumor invasion. Although some of these conditions may be associated with hemorrhage, it is usually not the primary reason why MRI/MRA/MRV is selected for the evaluation. A special condition where MRI may be superior to CT for evaluating hemorrhage is to detect an underlying neoplasm as the cause of bleeding (Abe, 2010).

POLICY HISTORY:

Review Date: May 2019

Review Summary:

- Added indications for visceral artery aneurysm; suspected chronic mesenteric ischemia; transjugular intrahepatic portosystemic shunt when US indicates suspected complications; imaging of deep inferior epigastric arteries for surgical planning (breast reconstruction surgery)
- Added Background information and updated references

Review Date: May 2020

Review Summary:

- Added compression syndromes for evaluation of vascular disease
- Added evaluation of FMD, Vascular Ehlers-Danlos syndrome, Loetz-Dietz
- Added May-Thurner
- Added to assess DVT in pregnant women vs serial compression ultrasound, to include pelvis
- Added indications for combo studies for chest MRA/abdomen and pelvis MRA

REFERENCES:

American College of Radiology (ACR). ACR Appropriateness Criteria®. <https://acsearch.acr.org/list>. Published 2014.

American College of Radiology (ACR). ACR Appropriateness Criteria®. <https://acsearch.acr.org/list>. Published 2017.

American College of Radiology (ACR). ACR Appropriateness Criteria®. <https://acsearch.acr.org/list>. Published 2018.

Bates, SM, Rajasekhar, A, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. *Blood Adv.* 2018; 2(22):3317-3359.

Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. *J Vasc Surg.* January 2018; 67(1):2-77.e2. [http://www.jvascsurg.org/article/S0741-5214\(17\)32369-8/fulltext#sec1.3](http://www.jvascsurg.org/article/S0741-5214(17)32369-8/fulltext#sec1.3). Retrieved February 15, 2018.

Farsad K, Kolbeck KJ. Clinical and radiologic evaluation of patients before TIPS creation. *AJR Am J Roentgenol.* 2014 Oct; 203(4):739-45.

Hartman R, Kawashima A. Radiologic evaluation of suspected renovascular hypertension. *Am Fam Physician.* August 1, 2009; 80(3):273-279. <https://www.aafp.org/afp/2009/0801/p273.html>. Retrieved February 15, 2018.

Ibrahim F, Dunn J, Rundback J, et al. Visceral artery aneurysms: Diagnosis, surveillance, and treatment. *Curr Treat Options Med.* 2018 Oct 26; 20(12):97.

Jesinger RA, Thoreson AA, Lamba R. Abdominal and pelvic aneurysms and pseudoaneurysms: Imaging review with clinical, radiologic, and treatment correlation. *Radiographics.* 2013; 33(3):E71-96. doi: 10.1148/rg.333115036.

Juntermanns B, Bernheim J, Karaindros K, et al. Visceral artery aneurysms. *Gefasschirurgie.* 2018; 23(Suppl 1):19-22.

Kadian-Dodov, D, Gornik, HL, et al. Dissection and Aneurysm in Patients with Fibromuscular Dysplasia: Findings from the US Registry for FMD. *Journal of the Am Coll of Cardiology.* 2016; 68(2.)

Khosa F, Krinsky G, Macari M, et al. Managing incidental findings on abdominal and pelvic CT and MRI, Part 2: White paper of the ACR Incidental Findings Committee II on vascular findings. *J Am Coll Radiol.* 2013; 10(10):789-794. doi:10.1016/j.jacr.2013.05.021.

Kumar Y, Hooda K, et al. Abdominal Aortic Aneurysm. Pictorial review of common appearance and complications. *Ann Transl Med.* 2017; 5(12):256.

Maki JH, Wilson GJ, Eubank WB. Navigator-gated MR angiography of the renal arteries: A potential screening tool for renal artery stenosis. *AJR Am J Roentgenol.* 2007; 188(6):W540-546. <http://www.ajronline.org/content/188/6/W540.long>.

Mazhar HR, Aeddula NR. Renal Vein Thrombosis. StatPearls. Treasure Island, FL. StatPearls Publishing; 2019-2018 Dec 26.

Michaely HJ, Attenberger UI, Kramer H, et al. Abdominal and pelvic MR angiography. *Magn Reson Imaging Clin N Am.* 2007; 15(3):301-314. <http://www.ncbi.nlm.nih.gov/pubmed/17893051>.

Mohler ER, Townsend RR. Advanced therapy in hypertension and vascular disease. 1st ed. Hamilton, Ontario: BC Decker, Inc; 2006. <http://books.google.com/books?hl=en&lr=&id=sCgURxhCJ-8C&oi=fnd&pg=PA224&dq=abdominal+cta+and+hypertension&ots=cJxa6qcpRr&sig=ahv53M5fWFAtE meLeNyfEFFErPo#PPA227,M1>.

Nael K, Saleh R, Lee M, et al. High-spatial-resolution contrast-enhanced MR angiography of abdominal arteries with parallel acquisition at 3.0 T: Initial experience in 32 patients. *AJR Am J Roentgenol.* 2006; 187:W77-85. <http://www.ajronline.org/content/187/1/W77.full.pdf+html>.

Owen JW, Saad NE, Foster G, et al. The feasibility of using volumetric phase-contrast MR imaging (4D Flow) to assess for transjugular intrahepatic portosystemic shunt dysfunction. *J Vasc Interv Radiol.* 2018 Dec; 29(12):1717-24.

Schwoppe RB, Alper HJ, Talenfeld AD. MR angiography for patient surveillance after endovascular repair of abdominal aortic aneurysms. *AJR Am J Roentgenol.* 2007; 188:W334-W340. <http://www.ajronline.org/content/188/4/W334.full.pdf+html>.

Shah A, Stavropoulos SW. Imaging surveillance following endovascular aneurysm repair. *Semin Intervent Radiol.* March 2009; 26(1):10-16. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036458/>.

Shih MC, Angle JF, Leung DA, et al. CTA and MRA in mesenteric ischemia: Part 2, normal findings and complications after surgical and endovascular treatment. *AJR Am J Roentgenol.* 2007a; 188:462-471. <http://www.ajronline.org/content/188/2/462.full.pdf+html>.

Shih MC, Hagspiel KD. CTA and MRA in mesenteric ischemia: Part 1, role in diagnosis and differential diagnosis. *AJR Am J Roentgenol.* 2007b; 188:452-461. <http://www.ajronline.org/content/188/2/452.full.pdf+html>.

Soulez G, Pasowicz M, Benea G, et al. Renal artery stenosis evaluation: diagnostic performance of gadobenate dimeglumine-enhanced MR angiography--comparison with DSA. *Radiology*. 2008; 247(1):273-285. <http://radiology.rsna.org/content/247/1/273.full.pdf+html>.

Textor SC, Lerman L. Renovascular hypertension and ischemic nephropathy. *Am J Hypertens*. 2010; 23(11):1159-1169. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078640/>.

Tullus K, Roebuck DJ, McLaren CA, et al. Imaging in the evaluation of renovascular disease. *Pediatr Nephrol*. June 2010; 25(6):1049-1056. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855432/>. Retrieved February 15, 2018.

Uberoi R, Tsetis D, Shrivastava V, et al. Standard of practice for the interventional management of isolated iliac artery aneurysms. *Cardiovasc Intervent Radiol*. 2011; 34(1):3-13. doi:10.1007/s00270-010-0055-0.

[Zucker, EJ, Ganguli, S, et al. Imaging of Venous Compression Syndromes. *Cardiovasc Diagn Ther*. 2016; 6\(6\):519-532.](#)

Reviewed / Approved by  M. Atif Khalid, M.D., Medical Director, Radiology
~~Reviewed / Approved by~~  ~~IP, Medical Director~~

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.